October 15, 2008 - Boston Scientific Corp. announced estimated U.S. market shares for September for its two drug-eluting ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
October 14, 2008
October 15, 2008 - The new name and branding for MEDRAD’s interventional products division was unveiled to the public at ...
October 14, 2008October 15, 2008 – At TCT 2008, Boston Scientific Corp. announced 12-month left main and three-vessel disease subset ...
October 14, 2008October 15, 2008 – Two-year results from the ENDEAVOR-IV clinical trial show that the Endeavor drug-eluting stent (DES) ...
October 14, 2008October 15, 2008 – The latest update to an independently conducted pooled data analysis shows that Medtronic’s Endeavor ...
October 14, 2008October 14, 2008 – Medtronic released, at TCT 2008, new data from the ENDEAVOR clinical program that reinforces the ...
October 13, 2008October 13, 2008 — Data from an independent meta-analysis of Abbott Vascular’s SPIRIT II and SPIRIT III randomized ...
October 13, 2008October 13, 2008 - Of those treated with Medtronic’s Endeavor Resolute drug-eluting stent (DES) in the RESOLUTE IDE ...
October 12, 2008October 13, 2008 – At TCT 2008, Boston Scientific Corp. announced results from an analysis of nearly 7,500 patients from ...
October 12, 2008October 13, 2008 - Boston Scientific Corp. released comprehensive data for the TAXUS ATLAS clinical program, a series of ...
October 12, 2008
October 10, 2008 - Boston Scientific Corp. today said it received FDA approval to market its second-generation ...
October 09, 2008October 9, 2008 - Boston Scientific Corp. yesterday said it completed enrollment in the PERSEUS trial, designed to ...
October 08, 2008October 8, 2008 - SurModics Inc. today said the PROTEX Coronary Stent System incorporating SurModics’ proprietary Finale ...
October 07, 2008September 30, 2008 – Czech Republic-based Tryton Medical Inc. said today it launched a novel Side Branch Stent System in ...
September 29, 2008September 25, 2008 - Boston Scientific Corp. announced it has received approval from the FDA to market its TAXUS ...
September 24, 2008© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now